SCHEMBL3052162

SCHEMBL3052162

CCSC=C1C(=O)Nc2ccc(C(=O)OC)cc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.58
AURKA O14965 1/20 0.57
RAF1 P04049 1/20 0.57
PSEN1 P49768 1/20 0.50
PSEN2 P49810 1/20 0.50
APH1B Q8WW43 1/20 0.50
NCSTN Q92542 1/20 0.50
APH1A Q96BI3 1/20 0.50
PSENEN Q9NZ42 1/20 0.50
IDO1 P14902 2/20 0.44
TDO2 P48775 2/20 0.44
TLK2 Q86UE8 9/20 0.43
HSP90AA1 P07900 1/20 0.43
TGM2 P21980 1/20 0.42
CDK1 P06493 2/20 0.42
CCNB1 P14635 2/20 0.42
CDYL2 Q8N8U2 1/20 0.41
CDYL Q9Y232 1/20 0.41
CDY1; CDY1B Q9Y6F8 1/20 0.41
JAK3 P52333 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5894610 0.80 PDPK1 (0.63) PDPK1AURKARAF1PSEN1PSEN2
SCHEMBL5894451 0.80 PDPK1 (0.63) PDPK1AURKARAF1PSEN1PSEN2
SCHEMBL22380701 0.76 PDPK1 (0.57) PDPK1AURKARAF1TGM2
SCHEMBL1965178 0.75 AURKA (0.69) PDPK1AURKARAF1PSEN1PSEN2
SCHEMBL12580695 0.75 AURKA (0.69) PDPK1AURKARAF1PSEN1PSEN2
SCHEMBL3052163 0.74 PDPK1 (0.53) PDPK1AURKARAF1PSEN1PSEN2
SCHEMBL5728671 0.74 PDPK1 (1.00) PDPK1TLK2CDK1CCNB1JAK3
SCHEMBL5361523 0.74 PDPK1 (1.00) PDPK1TLK2CDK1CCNB1JAK3
SCHEMBL10061664 0.73 PDPK1 (0.55) PDPK1AURKARAF1PSEN1PSEN2
SCHEMBL1395361 0.73 RAF1 (0.76) PDPK1AURKARAF1PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207179-B2 Substituted indolines as tyrosine kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-26 US disclosed
US-20100222331-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
EP-2181108-A2 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES Boehringer Ingelheim International GmbH (DE) 2010-05-05 EP disclosed
WO-2008152014-A2 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222331-A1 NEW COMPOUNDS CCNA1, CCNY, MKI67 PDPK1 1543/4885AURKA 1486/4885RAF1 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.